You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Pregnancy prevention programme

Toctino (alitretinoin), is licensed in the United Kingdom as an oral treatment for patients suffering from severe chronic hand eczema that does not respond to potent topical corticosteroid therapy. Toctino should only be prescribed by dermatologists or physicians with experience in the use of systemic retinoids.

Toctino (alitretinoin) is a naturally occurring, physiologic derivative of vitamin A and belongs to the well studied family of retinoids, which are all teratogens; therefore, Toctino (alitretinoin) is strictly contraindicated in pregnancy, and in women of child-bearing potential unless strict pregnancy testing and contraception is followed before, during and one month after cessation of treatment.

A summary of the requirements: Dear HCP letter

Download PDF

Guidance for healthcare professionals

Download PDF

Checklist for prescribing
to female patients

Download PDF

Acknowledgement form
for female patients

Download PDF

Contraception information
for patients

Download PDF

Patient information
booklet

Download PDF

 

Download all


All of the above documents are also available for download by clicking on the Risk Materials section on the European Medicines Compendium website. 

Toctino is a registered trademark of Stiefel Laboratories, Inc.